文献速递眼底病与葡萄膜炎青光眼

接受玻璃体腔抗血管内皮生长因子注射治疗的年龄相关性黄斑变性眼的青光眼风险、患病率与进展

Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
PubMed 文献 · Am J Ophthalmol · 2022-08-03

回顾性队列研究比较接受抗血管内皮生长因子(anti-VEGF)注射的渗出性年龄相关性黄斑变性(AMD)眼与无渗出性AMD(NEAMD)眼及无AMD眼,发现注射眼青光眼或疑似青光眼患病率及5年新诊断累积概率与对照组无差异,但注射眼所需局部降眼压药物更多、平均偏差下降速率大于无AMD眼。

要点

  • 抗VEGF注射眼与NEAMD眼或无AMD眼相比,青光眼或疑似青光眼患病率及5年新诊断累积概率均无显著差异。
  • 注射眼平均偏差变化速率与NEAMD眼相似,但大于无AMD眼(P = .02)。
  • 注射眼所需局部降眼压药物多于NEAMD眼(P = .03),激光治疗多于无AMD眼(P = .009)。

核心结论

  • 接受玻璃体腔抗VEGF注射治疗的渗出性AMD眼与对照组相比未增加青光眼发生风险。
  • 在已诊断青光眼的眼中,接受注射的渗出性AMD眼所需局部降眼压药物多于NEAMD眼,且平均偏差下降速率大于无AMD眼。

研究设计与样本

  • 回顾性临床队列研究,纳入2004年1月1日至2013年12月31日因渗出性AMD接受玻璃体腔抗VEGF注射的眼。
  • 对照组为年龄和性别匹配的NEAMD眼及无AMD眼。
  • 对已诊断青光眼或疑似青光眼的眼回顾注射详情、青光眼诊断类型和日期、治疗、标准自动视野计(SAP)及频域光学相干断层扫描(SD-OCT)。

主要发现

  • 抗VEGF注射眼707眼(504例患者),NEAMD及无AMD队列共1008眼。
  • 初始就诊时青光眼或疑似青光眼患病率:注射眼6.9% vs NEAMD眼9.7%(P = .22),vs 无AMD眼8.5%(P = .55)。
  • 抗VEGF注射后5年新诊断青光眼累积概率:注射眼1.9% vs NEAMD眼1.0%(P = .69),vs 无AMD眼1.6%(P = .88)。
  • 青光眼定性进展:注射眼 vs NEAMD眼 P = .19,vs 无AMD眼 P = .61。
  • 平均偏差变化速率:注射眼与NEAMD眼相似(P = .74),但大于无AMD眼(P = .02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the risk, prevalence, and progression of glaucoma development in age-related macular degeneration (AMD) eyes receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections compared to controls. DESIGN: Retrospective clinical cohort study. METHODS: Retrospective review of eyes receiving intravitreal anti-VEGF injections from January 1, 2004, to December 31, 2013, for exudative AMD. Age- and sex-matched control groups of eyes included eyes with nonexudative AMD (NEAMD) and no AMD. Eyes with a diagnosis of glaucoma or glaucoma suspect were reviewed for injection details, type and date of glaucoma diagnosis, glaucoma treatments, standard automated perimetry (SAP), and spectral domain optical coherence tomography (SD-OCT). Qualitative progression was determined by indication of glaucoma progression in provider notes. Quantitative progression was assessed based on change in mean deviation (MD) on SAP, retinal nerve fiber layer thickness on SD-OCT, and intraocular pressure (IOP). RESULTS: There were 707 eyes of 504 patients treated with anti-VEGF injections and 1008 eyes in the NEAMD and no-AMD cohorts. There was no difference in glaucoma or suspect prevalence at initial presentation between eyes treated with injections and NEAMD (6.9% vs 9.7%, P = .22) or no-AMD controls (vs 8.5%, P = .55). There was no difference in cumulative 5-year probability of new glaucoma diagnosis after anti-VEGF injections compared to NEAMD (1.9% vs 1.0%, P = .69) or no-AMD controls (vs 1.6%, P = .88). There was no difference in qualitative progression of glaucoma in the injection cohort vs NEAMD (P = .19) or no-AMD controls (P = .61). The rate of MD change in injection eyes was similar to NEAMD eyes (P = .74) but greater than no-AMD eyes (P = .02). Eyes receiving injections required more topical glaucoma medications compared with NEAMD (P = .03) and more glaucoma laser treatments compared with no-AMD controls (P = .009). Eyes receiving injections did not require more frequent incisional glaucoma surgery compared with NEAMD (21.0% vs 15.0%, P = .95) or no-AMD controls (vs 10.0%, P = .10). CONCLUSION: Eyes treated with intravitreal anti-VEGF injections for exudative AMD did not have increased risk of developing glaucoma compared with controls. Of those with a glaucoma diagnosis, exudative AMD eyes receiving injections required a greater number of topical glaucoma medications compared with NEAMD eyes and had a greater rate of MD loss than no-AMD controls.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shah SM, Boopathiraj N, Starr MR, et al. Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2022. PMID: 35932820. doi:10.1016/j.ajo.2022.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。